Operational Costs Compared: SG&A Analysis of Merus N.V. and Supernus Pharmaceuticals, Inc.

A Decade of SG&A: Merus N.V. vs. Supernus Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Merus N.V. and Supernus Pharmaceuticals, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Supernus Pharmaceuticals consistently outpaced Merus N.V. in SG&A spending, peaking at approximately 377 million in 2022, a staggering 10-fold increase compared to Merus N.V.'s peak of nearly 60 million in 2023. This disparity highlights Supernus's aggressive market expansion and investment in administrative capabilities. Meanwhile, Merus N.V.'s more conservative approach reflects a focus on streamlined operations. As the industry faces new challenges, understanding these financial strategies offers valuable insights into the companies' long-term visions and market positioning.